{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:06:05Z","timestamp":1789373165159,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["446653\/2024-1"],"award-info":[{"award-number":["446653\/2024-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107438","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:25:53Z","timestamp":1786253153000},"page":"107438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NMOSD and MOGAD in Latin America: A consensus-informed regional perspective"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-2689","authenticated-orcid":false,"given":"Vin\u00edcius","family":"Boldrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-1852","authenticated-orcid":false,"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Szejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107438_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106787","article-title":"Comparative analysis of AQP4-IgG-positive and AQP4-IgG-negative NMOSD: A multicenter study in Latin America","volume":"104","author":"Alonso","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106244","article-title":"Recommendations on NMOSD treatment in Latin America: utilizing consensus-based RAND\/UCLA methodology","volume":"94","author":"Alonso","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib3","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107438_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000551533","article-title":"Global prevalence of Neuromyelitis Optica spectrum disorder: a systematic review and meta-analysis with new data from Rio de Janeiro, Brazil","author":"Alvarenga","year":"2026","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2026.107438_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1590\/0004-282x-anp-2020-0527","article-title":"Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil","volume":"80","author":"Alves","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2026.107438_bib6","first-page":"001","article-title":"2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children","volume":"83","author":"Ap\u00f3stolos-Pereira","year":"2025","journal-title":"Arq. Neuropsiquiatr."},{"issue":"8","key":"10.1016\/j.msard.2026.107438_bib7","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: A review and meta-analysis","volume":"271","author":"Arnett","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib8","article-title":"Epidemiology of neuromyelitis optica spectrum disease in central-west Brazil: prevalence and associated clinical and demographic features","volume":"12","author":"Balduino Nogueira","year":"2026","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107438_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107438_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578817","article-title":"Limited availability of live CBA for AQP4-IgG testing and its consequences for the diagnosis and treatment of NMOSD in Latin American countries","volume":"411","author":"Boldrini","year":"2026","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107438_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107146","article-title":"Limited availability of live CBA for MOG-IgG testing and its consequences for the diagnosis and treatment of MOGAD in Latin American countries","volume":"109","author":"Boldrini","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106751","article-title":"Incorporation of the commercial kit for AQP4-IgG testing into the public health system: perspectives and new challenges for the diagnosis of Neuromyelitis Optica in Brazil","volume":"104","author":"Boldrini","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 \u2013 treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14728214.2025.2565189","article-title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape","volume":"30","author":"Carnero Contentti","year":"2025","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.msard.2026.107438_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/13524585221136259","article-title":"Frequency of NMOSD misdiagnosis in a cohort from Latin America: impact and evaluation of different contributors","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107438_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104611","article-title":"Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America","volume":"72","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105771","article-title":"Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)","volume":"89","author":"Carnero Contentti","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib20","article-title":"Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: a study from the RelevarEM registry","volume":"9","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107438_bib21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1177\/13524585231187120","article-title":"Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107438_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16445","article-title":"The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort","volume":"31","author":"Carnero Contentti","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1515481","article-title":"Application and interpretation of core elements of the 2015 NMOSD diagnostic criteria in routine clinical practice","volume":"15","author":"Carnero Contentti","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107438_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41393-018-0143-6","article-title":"Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders","volume":"56","author":"Carnero Contentti, Edgar","year":"2018","journal-title":"Spinal Cord."},{"key":"10.1016\/j.msard.2026.107438_bib27","article-title":"Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina","volume":"7","author":"Contentti","year":"2021","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107438_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102683","article-title":"Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","volume":"48","author":"Correa-D\u00edaz","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib29","article-title":"Inequalities in the health, nutrition, and wellbeing of afrodescendant women and children: a cross-sectional analysis of ten Latin American and Caribbean countries","volume":"15","author":"Costa","year":"2022","journal-title":"Lancet Reg. Heal. Am."},{"key":"10.1016\/j.msard.2026.107438_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578295","article-title":"Therapeutic plasma exchange for neuromyelitis optica attacks: evidence and challenges from a real-world cohort from Brazil","volume":"388","author":"De Almeida","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107438_bib31","first-page":"1342","article-title":"Poster 427 - Late breaking poster","volume":"31","year":"2025","journal-title":"Mult. Scler. J"},{"key":"10.1016\/j.msard.2026.107438_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102208","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort","volume":"44","author":"Edgar Patricio","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib33","article-title":"Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders","volume":"13","author":"Fang","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1055\/s-0043-1768669","article-title":"AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?","volume":"81","author":"Fragoso","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2026.107438_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103022","article-title":"Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico","volume":"52","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/1744-9987.13844","article-title":"Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders","volume":"26","author":"Gonzalez","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.msard.2026.107438_bib39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/neurolint14010023","article-title":"Neuromyelitis Optica spectrum Disorder in Central America and the Caribbean: a multinational clinical characterization study","volume":"14","author":"Gracia","year":"2022","journal-title":"Neurol. Int."},{"key":"10.1016\/j.msard.2026.107438_bib40","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104442","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Chile: lessons learned from challenging cases","volume":"69","author":"Guzm\u00e1n","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib42","series-title":"Health At a Glance","year":"2023"},{"key":"10.1016\/j.msard.2026.107438_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103750","article-title":"Sociodemographic and clinical characteristics of people with multiple sclerosis and neuro-myelitis optica spectrum disorder in a central northern region of Chile: a prevalence study","volume":"61","author":"Henr\u00edquez","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1056944","article-title":"Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107438_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102652","article-title":"Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study","volume":"47","author":"Ibis","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1575613","article-title":"Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)","volume":"16","author":"Kretschmer","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107438_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102807","article-title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","volume":"50","author":"Lana-Peixoto","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2026.107438_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib51","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107438_bib52","doi-asserted-by":"crossref","first-page":"103030","DOI":"10.1016\/j.msard.2021.103030","article-title":"The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2026.107438_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105130","article-title":"Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"81","author":"Martin","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1055\/s-0043-1777002","article-title":"Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience","volume":"81","author":"Messias","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2026.107438_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103733","article-title":"Neuromyelitis optica spectrum disorder in Western Mexico","volume":"61","author":"Mireles-Ram\u00edrez","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103677","article-title":"Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018","volume":"60","author":"Monsalve Mu\u00f1oz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib57","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107438_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2026.107438_bib59","article-title":"Expressions of inequalities in access to health services in Latin America: a scoping review","volume":"29","author":"Oliveira","year":"2024","journal-title":"Cien. Saude Colet."},{"key":"10.1016\/j.msard.2026.107438_bib60","article-title":"Latam-panorama-nmosd: epidemiological, clinical, and paraclinical features of neuromyelitis optica spectrum disorder in latin america and the caribbean, a systematic review and meta-analysis","volume":"102","author":"P","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of Neuromyelitis Optica","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107438_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106222","article-title":"MOG-IgG is rare in AQP4-IgG seronegative NMO phenotype in Brazil","volume":"93","author":"Pedrosa","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib63","article-title":"Realising the future: health challenges and achievements in Brazil","volume":"4","author":"Pimentel","year":"2023","journal-title":"SSM - Ment. Heal."},{"key":"10.1016\/j.msard.2026.107438_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06811","article-title":"PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia","volume":"7","author":"Restrepo-Aristiz\u00e1bal","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.msard.2026.107438_bib66","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic\u2019s disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104508","article-title":"Therapeutic strategies in NMOSD and MOGAD patients: a multicenter cohort study in Latin America","volume":"71","author":"Rojas","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106445","article-title":"Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative","volume":"98","author":"Rojas","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004572","article-title":"Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7342 individuals","volume":"10","author":"Ruiz-Linares","year":"2014","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.msard.2026.107438_bib71","first-page":"193","article-title":"Neuromyelitis optica spectrum disorders: profile of a cohort according to the 2015 diagnostic criteria","volume":"65","author":"RUribe-San Martin","year":"2017","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib72","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/acn3.52310","article-title":"Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay","volume":"12","author":"Said","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105452","article-title":"Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: a cohort study","volume":"83","author":"San Martin","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib74","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107438_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578781","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): practical recommendations for diagnosis and management","volume":"410","author":"Sechi","year":"2026","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2026.107438_bib76","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107438_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106160","article-title":"Early rituximab versus escalating therapy in neuromyelitis optica: a cost and quality of life analysis","volume":"92","author":"Silva","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fped.2020.00339","article-title":"Pediatric NMOSD: A review and position statement on approach to work-up and diagnosis","volume":"8","author":"Tenembaum","year":"2020","journal-title":"Front Pediatr."},{"key":"10.1016\/j.msard.2026.107438_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104485","article-title":"Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort","volume":"70","author":"Tkachuk","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104915","article-title":"Prevalence of neuromyelitis optica spectrum disorder in Colombia: analysis of the official ministry of health administrative registry","volume":"78","author":"Torres-Camacho","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107438_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2026.107438_bib83","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00415-025-13425-1","article-title":"Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study","volume":"272","author":"Tun\u00e7","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107438_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105018","article-title":"Neuromyelitis optica spectrum disorders in Argentina: a hospital-based study","volume":"79","author":"Villa","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107438_bib85","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/00207454.2016.1254630","article-title":"Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders","volume":"127","author":"Zhang","year":"2016","journal-title":"Int. J. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:06:47Z","timestamp":1789369607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"alternative-id":["S2211034826004736"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107438","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NMOSD and MOGAD in Latin America: A consensus-informed regional perspective","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107438"}}